Table 1.
Effect of somatic mutations on outcomes after treatment with hypomethylating agents
| Gene mutation | Effect on OS | Effect on ORR | ||
|---|---|---|---|---|
| Number of patients with mutations/overall number of patients (reference) | Number of patients with mutations/overall number of patients (reference) | |||
| Shorter OS* | No differences | Lower ORR | No differences | |
| TP53 | 39/213 (20) | 21/116 (30)† | 21/116 (30)†‡ | 39/213 (20) |
| 20/134 (21) | 20/134 (21) | |||
| 13/107 (22)* | 13/107 (22)* | |||
| 38/168 (23) | 38/168 (23) | |||
| 10/114 (24) | 10/114 (24) | |||
| 11/84 (25) | 11/84 (27) | |||
| 38/213 (29) | 38/213 (29) | |||
| TET2 | 13/86 (25) | 58/213 (20) | 58/213 (20) | 26/134 (21) |
| 26/134 (21) | 13/86 (25) | 17/107 (22)* | ||
| 17/107 (22)* | 17/92 (26) | 29/79 (23) | ||
| 29/79 (23) | 33/114 (24) | |||
| 33/114 (24) | 32/84 (27) | |||
| 17/92 (26) | 86/357 (28) | |||
| 32/84 (27) | 58/213 (29) | |||
| 86/357 (28) | ||||
| 58/213 (29) | ||||
| DNMT3A | 9/107 (23)* | 34/213 (20) | 34/213 (20) | |
| 10/134 (21) | 10/134 (21) | |||
| 6/168 (23) | 9/107 (22)* | |||
| 7/114 (24) | 6/168 (23) | |||
| 8/92 (26) | 7/114 (24) | |||
| 18/84 (27) | 8/92 (26) | |||
| 34/213 (29) | 18/84 (27) | |||
| 34/213 (29) | ||||
| ASXL1 | 99/213 (21) | 20/107 (22)* | 99/213 (20) | |
| 29/134 (22)§ | 17/79 (23) | 20/134 (21) | ||
| 24/92 (27) | 23/114 (24) | 20/107 (22)* | ||
| 11/84 (27) | 17/79 (23) | |||
| 96/357 (28) | 23/114 (24) | |||
| 98/213 (29) | 24/92 (26) | |||
| 11/84 (27) | ||||
| 96/357 (28) | ||||
| 98/213 (29) | ||||
| RUNX1 | 18/84 (27) | 17/134 (21) | 42/213 (20) | |
| 42/213 (20) | 12/107 (22)* | 17/134 (21) | ||
| 20/79 (23) | 12/107 (22)* | |||
| 16/114 (24) | 20/79 (23) | |||
| 43/213 (29) | 16/114 (24) | |||
| 18/84 (27) | ||||
| 43/213 (29) | ||||
| EZH2 | 17/84 (27) | 10/107 (22)* | 21/213 (20) | |
| 12/134 (21)§ | 2/168 (23) | 12/134 (21) | ||
| 21/213 (20) | 5/114 (24) | 10/107 (22)* | ||
| 2/168 (23) | ||||
| 5/114 (24) | ||||
| 17/84 (27) | ||||
| RAS | 12/107 (22)* | 24/213 (20) | 8/168 (23) | 24/213 (20) |
| 12/134 (21) | 12/134 (21) | |||
| 8/168 (23) | 12/107 (22)* | |||
| 8/114 (24) | 8/114 (24) | |||
| 14/84 (27) | 14/84 (27) | |||
| SRSF2 | 35/213 (20) | 35/213 (20) | ||
| 24/134 (21) | 24/134 (21) | |||
| 1/107 (22)* | 1/107 (22)* | |||
| 11/53** (23) | 11/53** (23) | |||
| 27/114 (24) | 27/114 (24) | |||
| 34/213 (24,29) | 34/213 (29) | |||
| U2AF1 | 29/213 (20) | 21/107 (22)* | 29/213 (20) | |
| 5/134 (21) | 5/134 (21) | |||
| 21/107 (22)* | 13/53 (23) | |||
| 13/53 (23) | 6/114 (24) | |||
| 6/114 (24) | 12/84 (25) | |||
| 12/84 (27) | 53/357 (28) | |||
| 53/357 (28) | 30/213 (29) | |||
| 30/213 (29) | ||||
ORR, overall response rate.
*
Azacitidine-treated patients.
†
Decitabine-treated patients (type of hypomethylating agent used not specified in remaining series).
‡
Higher ORR.
§
Longer OS.